CUPERTINO, Calif., Nov. 28, 2018 /PRNewswire-PRWeb/ -- Protein Metrics Inc., a leading provider of mass spectrometry software for protein characterization, announced today it has received an FDA RFQ award to use its Byos™ platform for LC-MS multi-attribute method (MAM) analysis of protein therapeutics.
"We are thrilled that the FDA has chosen to investigate MAM approaches with Protein Metrics software," says Eric Carlson, Ph.D., President and CEO. "While we recognize that this award does not constitute an endorsement, we are extremely pleased that the FDA recognized the strength and utility of our Byos MAM workflows."
Within the Protein Metrics Byos platform, users can launch automated workflows for MAM Reference Characterization, MAM Chromatogram Annotation (in-silico), MAM Chromatogram Annotation (LC-MS/MS), and MAM New Peak Detection. The easy, consistent user interface of Byos supports all MAM users – from characterization experts to research associates and analysts.
To learn more about Protein Metrics MAM, register for the Dec. 6, 2018 webinar, "An Implementation of Vendor-Neutral Multi-Attribute Method (MAM)" featuring Ben Niu, Ph.D., of MedImmune, and visit http://www.proteinmetrics.com/mam
About Protein Metrics Protein analysis should never be limited by software. With a clear focus on protein characterization, Protein Metrics' vendor-neutral software allows scientists to use data generated on analytical instruments like mass spectrometers to quickly identify and report protein sequences as well as any variations from the expected form. We innovate so that biopharmaceutical companies and university research labs can achieve confident results from their analysis and reporting. With our customers, we are boldly advancing protein characterization. Protein Metrics is headquartered in Cupertino, CA at the crossroads of computing and biotechnology in the San Francisco Bay Area. For more information, visit http://www.proteinmetrics.com.
SOURCE Protein Metrics
Advertisement
"We are thrilled that the FDA has chosen to investigate MAM approaches with Protein Metrics software," says Eric Carlson, Ph.D., President and CEO. "While we recognize that this award does not constitute an endorsement, we are extremely pleased that the FDA recognized the strength and utility of our Byos MAM workflows."
Advertisement
Within the Protein Metrics Byos platform, users can launch automated workflows for MAM Reference Characterization, MAM Chromatogram Annotation (in-silico), MAM Chromatogram Annotation (LC-MS/MS), and MAM New Peak Detection. The easy, consistent user interface of Byos supports all MAM users – from characterization experts to research associates and analysts.
To learn more about Protein Metrics MAM, register for the Dec. 6, 2018 webinar, "An Implementation of Vendor-Neutral Multi-Attribute Method (MAM)" featuring Ben Niu, Ph.D., of MedImmune, and visit http://www.proteinmetrics.com/mam
About Protein Metrics Protein analysis should never be limited by software. With a clear focus on protein characterization, Protein Metrics' vendor-neutral software allows scientists to use data generated on analytical instruments like mass spectrometers to quickly identify and report protein sequences as well as any variations from the expected form. We innovate so that biopharmaceutical companies and university research labs can achieve confident results from their analysis and reporting. With our customers, we are boldly advancing protein characterization. Protein Metrics is headquartered in Cupertino, CA at the crossroads of computing and biotechnology in the San Francisco Bay Area. For more information, visit http://www.proteinmetrics.com.
SOURCE Protein Metrics
